1.	A Study of Immunotherapy With TIL (Tumor Infiltrating Lymphocytes) in Combination With Intra-tumoral Injections of Interferon Gamma-adenovirus (Ad-IFNg) in Patients With Stage IIIc or Stage IV Metastatic Melanoma (AJCC)(Protocol TIL-Ad-INFg) Phase: Phase II, Phase I Type: Treatment Status: Active Age: 18 to 75 Sponsor: Other Protocol IDs: 09/5-R, 2009-013087-38, NCT01082887
2.	Cell Therapy for Metastatic Melanoma Using CD8 Enriched Tumor Infiltrating Lymphocytes Phase: Phase II, Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: 110011, 11-C-0011, NCT01236573
3.	Phase II Study With Immunotherapy With Dendritic Cells and Tumor Infiltrating Lymphocytes in Solid Tumors Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: CD-2007-01, NCT00610389
4.	Prospective Randomized Study of Cell Therapy for Metastatic Melanoma Using Short-Term Cultured Tumor Infiltrating Lymphocytes Plus IL-2 Following Either a Non-Myeloablative Lymphocyte Depleting Chemotherapy Regimen Alone or in Conjunction w/1200 TBI Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: 110123, 11-C-0123, NCT01319565
5.	Modified Tumor Infiltrating Lymphocytes for Metastatic Melanoma Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: 110163, 11-C-0163, NCT01369875
6.	A Pilot Study of the Administration of Young Tumor Infiltrating Lymphocytes Following a Non-Myeloablative Lymphocyte Depleting Chemotrheraphy Regimen in Metastatic Melanoma Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: 110260, 11-C-0260, NCT01468818
7.	A Phase II Study of Lymphodepletion Followed by Autologous Tumor-Infiltrating Lymphocytes and High-Dose Adesleukin for Human Papillomavirus-Associated Cancers Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: 120116, 12-C-0116, NCT01585428
8.	Vemurafenib With Lymphodepletion Plus Adoptive Cell Transfer & High Dose IL-2 Metastatic Melanoma Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: MCC-16992, NCT01659151
9.	A Study of Adoptive Immunotherapy With Autologous Tumor Infiltrating Lymphocytes in Solid Tumors Phase: Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 to 70 Sponsor: Other Protocol IDs: SenU-200902002-2, NCT01462903
10.	Vemurafenib and White Blood Cell Therapy for Advanced Melanoma Phase: Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: 120114, 12-C-0114, NCT01585415
11.	Lymphodepletion Plus Adoptive Cell Transfer With High Dose IL-2 in Patients With Metastatic Melanoma Phase: No phase specified Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: MCC-15781, NCT01005745